100% Quality Guarantee
PhD-Level Technical Support
Key Features

PE/GenieFluor 594 Anti-Human CD37 Antibody [IPO-24] (AGEL3356)

SKU AGEL3356
Product Type Antibody
Antibody Type Monoclonal Antibody
Applications FCM
Reactivity Human
Host Species Mouse
Isotype Mouse IgG2b, k
Clone IPO-24
Conjugation PE/AF594
€144 - €532

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

PE/GenieFluor 594 Anti-Human CD37 Antibody [IPO-24]

The PE-GenieFluor 594 Anti-Human CD37 Antibody (IPO-24) from Assay Genie is a cutting-edge tool for researchers studying the CD37 protein, a cell surface antigen associated with various immune functions. This highly specific antibody is meticulously designed to target human CD37, facilitating precise detection and analysis in a range of cell types. With its optimized formulation, researchers can confidently explore the role of CD37 in immunology and cancer research applications.CD37, a transmembrane glycoprotein, is known for its involvement in B cell signaling and development, making it a key player in immune response modulation.

By utilizing the PE-GenieFluor 594 Anti-Human CD37 Antibody (IPO-24), researchers can delve into the mechanisms underlying B cell function, immune regulation, and potential implications in disease states such as leukemia and lymphoma. This antibody opens up new avenues for investigating CD37-related pathways and developing targeted therapies in the realm of immunotherapy.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose